Clinical trials
catalyst calendar across sponsors →Studies where ELVN is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional
Held by 11 tracked-famous managers (CITADEL ADVISORS LLC, Balyasny Asset Management L.P., MARSHALL WACE, LLP, MILLENNIUM MANAGEMENT LLC, D. E. Shaw & Co., Inc., +6 more) · FINRA short interest 11.4 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 15 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese ParticipantsNCT06787144Part 1: Incidence of dose limiting toxicitiesNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: ELVN-001 | CML (Chronic Myelogenous Leukemia), Chronic Phase CML | 21 | Jan 2028 | ≤ 529 d | 2025-07-01 |
| A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid LeukemiaNCT05304377Phase 1a: Incidence of dose limiting toxicitiesNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: ELVN-001 | Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml | 250 | Dec 2027 | ≤ 498 d | 2026-04-01 |
| ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast CancerNCT06328738Incidence of dose limiting toxicities (DLTs; Phase 1a only)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: ELVN-002, Trastuzumab, 5-Fluorouracil, Oxaliplatin, Capecitabine, Eribulin, paclitaxel, Leucovorin | HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification, Colorectal Cancer | 275 | Jan 2027 | ≤ 164 d | 2025-11-19 |
| ELVN-002 in HER2 Mutant Non-Small Cell Lung CancerNCT05650879Incidence of dose limiting toxicities in Phase 1a monotherapyNon-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Trastuzumab emtansine | HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification | 198 | Jul 2026 | — | 2025-07-15 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19